Skip to content
No results
Home
About
Executive Team
Board of Directors
Strategic Collaborations
Careers
Products
Zabadinostat (CXD101)
PRMT5 Inhibitor (AT101)
Cancer Vaccine (PCV001)
Press Releases
Pipeline
Publications
Contact
Home
About
Executive Team
Board of Directors
Strategic Collaborations
Careers
Products
Zabadinostat (CXD101)
PRMT5 Inhibitor (AT101)
Cancer Vaccine (PCV001)
Press Releases
Pipeline
Publications
Contact
Search
Menu
ESMO 2016 Poster 1
May 2, 2016
ESMO-2016-Poster-1
Share This Post
X
Facebook
LinkedIn
Messenger
WhatsApp
Posts navigation
← Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2) →
More Posts
Interim Phase 2 Results Suggest Zabadinostat Combination Improves Overall Survival in Advanced Liver Cancer
February 26, 2025
IngenOx Therapeutics Chief Medical Officer Meets Chinese Premier to Advance International Anti-Cancer Cooperation
February 10, 2025
IngenOx Therapeutics CMO Receives China Friendship Medal
October 21, 2024
